Emapticap pegol

Drug Profile

Emapticap pegol

Alternative Names: NOX-E36

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Nucleotide aptamers; Polyethylene glycols
  • Mechanism of Action Chemokine CCL2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I Solid tumours

Most Recent Events

  • 26 Jul 2016 Chemical structure information added
  • 22 Jul 2016 Phase-I clinical trials in Solid tumours (In volunteers) (unspecified route) before July 2016
  • 22 Jul 2016 NOXXON Pharma completes a phase I trial in volunteers in (NOXXON Pharma pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top